曲美他嗪对不稳定型心绞痛的治疗作用分析

Analysis of the Therapeutic Effect of Trimetazidine on Unstable Angina Pectoris

目的探讨在治疗不稳定型心绞痛患者中采用曲美他嗪药物的临床价值。方法选取2019年1月—2021年6月期间该院收治的不稳定型心绞痛患者共计78例,采用双色球分组法将患者平均分成两组,对照组采用瑞舒伐他汀治疗,研究组采取曲美他嗪治疗,对比两组的治疗总有效率、治疗前后心功能及血脂指标、生活质量和心绞痛发作情况。结果研究组的临床总体治疗有效率(94.87%)较对照组的79.49%明显提高,差异有统计学意义(χ^(2)=4.129,P<0.05);研究组患者治疗后Hcy(12.31±2.11)μmol/L、LVEF/RVEF(60.84±3.63)%、CI(3.23±0.32)L/(min·m^(2))、CO(7.83±0.63)L/min、TC(1.91±0.21)mmol/L、TG(4.41±0.21)mmol/L改善情况较对照组更明显,差异有统计学意义(t=7.767、8.963、6.272、21.315、8.158、17.562,P<0.05);研究组患者生活质量评分中认知功能(87.93±1.48)分、躯体功能(87.90±1.42)分、情感功能(87.71±1.51)分、角色功能(87.32±1.89)分、社会功能(89.01±2.05)分提升程度较对照组患者更明显,差异有统计学意义(t=11.354、14.992、13.273、10.548、11.191,P<0.05);研究组患者心绞痛发作频率(2.11±0.32)次/周、心绞痛持续时间(2.82±0.24)min/次较对照组患者明显减少,差异有统计学意义(t=19.514、24.053,P<0.05)。结论对不稳定型心绞痛患者采取曲美他嗪治疗可改善心功能,减少心绞痛发作次数,提高生活质量,建议推广应用。

Objective To investigate the clinical value of trimetazidine in the treatment of patients with unstable angina pectoris.Methods A total of 78 patients with unstable angina pectoris admitted to the hospital from January 2019 to June 2021 were selected.The patients were divided into two groups evenly by the two-color ball grouping method.The control group was treated with rosuvastatin,and the study group was treated with trimetazidine.The total effective rate of treatment,heart function and blood lipid indexes before and after treatment,quality of life and angina pectoris were compared between the two groups.Results The overall effective rate of clinical treatment in the study group was 94.87%compared with 79.49%in the control group,and the difference was statistically significant(χ^(2)=4.129,P<0.05);after treatment,the improvement of Hcy(12.31±2.11)μmol/L,LVEF/RVEF(60.84±3.63)%,CI(3.23±0.32)L/(min·m^(2)),CO(7.83±0.63)L/min,TC(1.91±0.21)mmol/L,TG(4.41±0.21)mmol/L,in the study group was more obvious that in than the control group,the difference was statistically significant(t=7.767,8.963,6.272,21.315,8.158,17.562,P<0.05);the quality of life scores of patients in the study group included cognitive function(87.93±1.48)points,physical function(87.90±1.42)points,emotional function(87.71±1.51)points,role function(87.32±1.89)points,and social function(89.01±2.05)points,the degree of improvement was more obvious than that of patients in the control group,the difference was statistically significant(t=11.354,14.992,13.273,10.548,11.191,P<0.05).The frequency of angina pectoris in the study group was(2.11±0.32)times/week and the duration of angina pectoris(2.82±0.24)min/time was significantly lower than those in the control group,the difference was statistically significant(t=19.514,24.053,P<0.05).Conclusion Trimetazidine treatment for patients with unstable angina can improve heart function,reduce the number of angina pectoris,and improve the quality of life.It is recommended to be popularized and applied.